Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities
John Varga, Maria Trojanowska, Masataka Kuwana · Journal of Scleroderma and Related Disorders · 2017
Systemic sclerosis (SSc) is a complex disease characterized by early microvascular abnormalities, immune dysregulation and chronic inflammation, and subsequent fibrosis of the skin and internal organs. Excessive fibrosis, distinguishing hallmark of SSc, is the end result of a complex series of interlinked vascular injury and immune activation, and represents a maladaptive repair process. Activated vascular, epithelial, and immune cells generate pro-fibrotic cytokines, chemokines, growth factors, lipid mediators, autoantibodies, and reactive oxygen species. These paracrine and autocrine cues in turn induce activation, differentiation, and survival of mesenchymal cells, ensuing tissue fibrosis through increased collagen synthesis, matrix deposition, tissue rigidity and remodeling, and vascular rarefaction. This review features recent insights of the pathogenic process of SSc, highlighting three major characteristics of SSc, microvasculopathy, excessive fibrosis, and immune dysregulation, and sheds new light on the understanding of molecular and cellular mechanisms contributing to the pathogenesis of SSc and providing novel avenues for targeted therapies.
Cited by 323 works. doi:10.5301/jsrd.5000249
Authors
References
- TLR4 enhances TGF-β signaling and hepatic fibrosis
- SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
- Fibrotic disease and the TH1/TH2 paradigm
- Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites
- Formation and Function of the Myofibroblast during Tissue Repair
- Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
- Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty‐year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis
- Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis
- The emerging roles of YAP and TAZ in cancer
- Transduction of mechanical and cytoskeletal cues by YAP and TAZ